Introduction
Apolipoprotein E (ApoE) is a 34-kDa protein encoded by a gene on human chromosome 19. ApoE is a major component of lipoproteins and plays an important role in cholesterol transport. ApoE may be involved in cholesterol transport into neurons, thus playing an important role in neuronal growth and in the central nervous system response to injury, particularly in the hippocampal region (1) .
The ApoE gene is polymorphic, and three alleles (e2, e3, e4) that dier in amino acids at positions 112 and 158 have been described. The e4 allele has been linked to an increased risk of developing lateonset Alzheimer's disease (AD) (2±8). In addition, e4-carriers would have an earlier onset of AD, compared with e3e3 (9, 10), while the e2 allele would confer a protective role, delaying age of onset of AD (11) . In addition to its role in AD, ApoE-variation has been associated with vascular dementia and Lewy body dementia (12, 13) , a fact that supports an important role for ApoE in neuropsychiatric disorders.
Because the ApoE-genotypes may in¯uence the phenotype of several neuropsychiatric disorders, it has been proposed as a non-speci®c risk factor that would modify the risk conferred by other more speci®c factors (14, 15) . Schizophrenia is a complex genetic disorder that would involve variation at several genes of small eect (16) . The genetic association between the e4 allele and AD and other neuropsychiatric diseases, plus the clinical similarities between chronic schizophrenic patients and these with AD (cognitive impairment, psychotic symptoms, and changes of behavioral and aective patterns) have led several authors to investigate the role of the ApoE genotypes and schizophrenia.
A role for ApoE-alleles in schizophrenia has been reported by some authors, but not others. Thus, an increased e4-frequency in patients compared with controls has been described (14) , while others found a decreased e4-frequency (17, 18) . In addition, ApoE e4-frequency was lower in schizophrenics with progressive dementia and late paraphrenia (19, 20) , and at least one study has reported an earlier age of onset for adult (15) . However, this association between ApoE e4 and the age of onset was not found by others (21) . Most of the studies did not support a role for the variation at the ApoE and schizophrenia (15, 21±31) .
A relationship between ApoE-genotypes and the clinical course of the disease has been reported. Thus, Pickar et al. (32) found signi®cantly lower psychosis scores among e4-carriers (although the distribution of the genotypes was consistent with a lack of association between ApoE and the risk of developing the disease). In opposition to these authors, Ohara et al. (33) reported no dierence in clinical characteristics between patients with and without the e4-allele. Finally, Rietschel et al. (34) suggested that positive symptoms of`incoherence', speech dicult to understand', and`persecutory delusions' are preferentially displayed by ApoE e4-carriers but who manifested less severe positive symptoms of schizophrenia than patients who do not carry this allele.
In order to clarify the possible association between the variation at the APoE-gene and schizophrenia, we analysed a group of schizophrenic patients and matched controls. The possible association between ApoE-genotypes and age of onset of the disease has also been investigated.
Material and methods

Subjects
One hundred and six schizophrenic out-patients from the region of Asturias (Northern Spain, total population 1 million) were enrolled in the study. All patients had a diagnosis of schizophrenia according to Diagnostic Statistic Manual IV (DSM-IV) criteria, and the age of onset was the age at which symptoms were of sucient degree to meet the DSM-IV criteria for schizophrenia (15) .
Two hundred and ®fty healthy volunteers (hospital sta and blood donors), matched with the patients for age and ethnicity, were also genotyped. The study was conducted according to the provisions of the World Medical Association Declaration of Helsinki, and ethical approval of the study was granted (35) .
ApoE genotyping
Genomic DNA was extracted from leukocytes in 10 ml of peripheral blood. ApoE-genotyping was performed as previously described (36) . Brie¯y, 100 ng of genomic DNA were polymerase chain reaction (PCR)-ampli®ed with primers TCCAAG-GAGCTGCAGGCGGCGCA and ACAGAATT-CGCCCCGGCCTGGTACACTGCCA. After 35 cycles of ampli®cation, reactions were digested with the restriction enzyme CfoI, and the digestedfragments were separated by electrophoresis on a 4% ethidium-bromide-stained agarose gel. Allele assignment was based on the presence or absence of CfoI cutting sites in the ampli®ed sequence.
Statistical analysis
Dierences between allele and genotype frequencies were assessed using a v 2 test or Fisher's exact test, and P £ 0.05 was considered as signi®cant. Odds ratios (ORs) and their con®dence intervals (95% CIs) were also calculated. The relationship between ApoE-genotypes and age of onset was explored in two ways (15) . First, the cohort was divided into two groups based on the presence or absence of at least one e4-allele, and these groups were compared using Student's t-test. Secondly, in order to de®ne a possible dose±eect relationship, we graded each genotype on a ®ve-point scale, with the e2e2 representing the lowest point and ApoE e4e4 the highest point (1 e2e2, 2 e2e3, 3 e3e3 or e2e4, 4 e3e4, 5 e4e4). This allowed us to account for a possible protective eect of the e2 allele when added against the presumed neutral eect of e3 and the negative eect of e4 (15) . The SPSS/PC+ sofware was used for the statistical analyses.
The sample-size required to reach a power of 80, at a signi®cance level (a) of 0.05, was also calculated.
Results
We genotyped 106 schizophrenic out-patients (DSM-IV criteria) [mean age (SD): 35.1 (10.3) years; males: 55.6% (60 patients)] and 250 healthy volunteers [mean age (SD): 46 (15.0) years; males 48% (120 subjects)]. The ApoE-genotypes distribution in schizophrenics and controls is summarized in Table 1 . Genotype frequencies did not dier between patients andcontrols (P 0.399).However, an increased frequency of e4-carriers (e3e4 + e4e4) was found in patients compared with controls (P 0.096; OR 1.60; 95% CI 0.86±2.99) ( Table 2 ). To reach a power of 80 (at a signi®cance level a 0.05), a total of 441 patients and 1041 controls should be analysed. Allele frequencies did not dier between the two groups (P 0.124; OR 1.49; 95% CI 0.82±2.70) ( Table 3) .
The mean age of onset for e4-carriers (e3e4, e4e4) was 26.62 (11.77), compared with 25.56 (8.70) among the e4-negative patients. This dierence between groups was not signi®cant (t ±0.343, P 0.736). Age of onset did not correlate with ApoE grade (r 0.088, P 0.407).
Discussion
To our knowledge this is one of the ®rst reports analysing the association between the ApoEpolymorphism and schizophrenia in the Spanish population. Our data do not support a role for ApoE-genotypes in schizophrenia, a result that is in agreement with previous reports (15, 21±31). Although carriers of the e4-allele were at a higher frequency among the patients, the dierence did not reach a statistical signi®cance (P 0.096), and the size of the patients and controls required to reach a power of 80 (at a signi®cance level a 0.05) was too high. In opposition to these authors, Harrington et al. (14) described an increased frequency of the e4-allele among schizophrenics, while Igata-Yi et al. (17) and Chen et al. (18) found a decreased e4-frequency in patients.
There are several explanations for this discrepancy (25) . First, the association between ApoEgenotypes and schizophrenia could dier between dierent populations (37) . Secondly, positive ®nd-ings could be because of selection bias or type II errors as a consequence of a reduced sample-size. To further con®rm previous results, Town et al. (27) combined the data of three studies (14, 23, 27) , increasing the power to 93 (thus reducing the likelihood of a type II error), and again found no association between e4-carriers status and schizophrenia diagnosis (v 2 0.376, P 0.540). Thirdly, the criteria for diagnosis of schizophrenia in the postmortem cohort studied by Harrington et al. (14) were not speci®ed. Arnold et al. (38) described wrong diagnostic classi®cation in as high as 50% of the cases, when only listed chart diagnosis were used without application of more rigorous criteria in chart review or patient examination. Fourthly, because the diagnosis of schizophrenia is based on symptom-oriented criteria, the selection of cases according to the same criteria does not assure etiologically homogeneous patients in dierent studies (25) . Fifthly, patients recruited from a out-patient service could have a less severe psychopathology, and the discrepancies between the studies could be a consequence of the dierences in the nature of the sample source.
No patient in our sample has the e4e4 genotype. This is in agreement with previous reports (18, 21, 25, 33) . As the e4 allele is signi®cantly associated with the development of AD, this ®nding may partially explain why the AD neuropathology is infrequent in demented schizophrenic subjects (39) . In addition, e4-carriers have higher plasma cholesterol levels compared with non-carriers (40) , a ®nding that is in agreement with previous reports that described lower cholesterol levels in schizophrenics compared with healthy controls (41) . The lack of association with ApoE expression found in our study may provide evidence for alternative molecular mechanisms underlying the dementia in schizophrenia and AD.
Our results are similar to those of Kimura et al. (21) and do not support an involvement of the e4-allele in the age of onset of schizophrenia (15) . The cause of such discrepancy is uncertain, but could be the result of ethnic or environmental dierences. This explanation is supported by the fact that the association between the ApoE-genotype and AD would be race-dependent (42) . Another important factor could be the dierences in the methodology used for determining the age of onset. However, our method was similar to that used by Arnold et al. (15) . Finally, as Arnold et al. (15) suggested, it is also possible that their result is a false positive. In conclusion, the results of our study are in accordance with previous results reports, and do not support a role for the ApoE e4 allele in schizophrenia. However, further studies in schizophrenic patients with severe cognitive dysfunction may help to clarify the relationship, if any, between ApoE and schizophrenia.
